Gilead Sciences Reports Phase 3 TROPICS-02 Results for Trodelvy in HR-Positive Breast Cancer

Gilead Sciences today announced results from the Phase 3 TROPICS-02 trial evaluating Trodelvy (sacituzumab govitecan) versus chemotherapy in patients with HR-positive, HER2-negative metastatic breast cancer who had received prior endocrine therapy and chemotherapy. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with Trodelvy.